Now showing items 1-1 of 1

    • Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. 

      Zatreanu, D; Robinson, HMR; Alkhatib, O; Boursier, M; Finch, H; Geo, L; Grande, D; Grinkevich, V; Heald, RA; Langdon, S; Majithiya, J; McWhirter, C; Martin, NMB; Moore, S; Neves, J; Rajendra, E; Ranzani, M; Schaedler, T; Stockley, M; Wiggins, K; Brough, R; Sridhar, S; Gulati, A; Shao, N; Badder, LM; Novo, D; Knight, EG; Marlow, R; Haider, S; Callen, E; Hewitt, G; Schimmel, J; Prevo, R; Alli, C; Ferdinand, A; Bell, C; Blencowe, P; Bot, C; Calder, M; Charles, M; Curry, J; Ekwuru, T; Ewings, K; Krajewski, W; MacDonald, E; McCarron, H; Pang, L; Pedder, C; Rigoreau, L; Swarbrick, M; Wheatley, E; Willis, S; Wong, AC; Nussenzweig, A; Tijsterman, M; Tutt, A; Boulton, SJ; Higgins, GS; Pettitt, SJ; Smith, GCM; Lord, CJ (2021-06-17)
      To identify approaches to target DNA repair vulnerabilities in cancer, we discovered nanomolar potent, selective, low molecular weight (MW), allosteric inhibitors of the polymerase function of DNA polymerase Polθ, including ...